Last updated: February 20, 2026
What is the scope of patent MY144616?
Patent MY144616, granted by Malaysia's Intellectual Property Corporation (MyIPO), covers a specific pharmaceutical compound, composition, or method of use. Exact details of the patent's scope depend on its claims, which define the legal protection.
Based on the available patent filings and related documents, MY144616 primarily protects:
- A novel chemical entity or a combination of active ingredients with specific structural features or modifications.
- Methods of manufacturing or synthesizing the compound.
- Therapeutic uses of the compound for certain indications.
The patent's claims level define if it protects a chemical composition, a formulation, a particular method of treatment, or a use-related invention.
What are the core claims of MY144616?
While the official patent document (issued on [publication date]) is the primary source, typical claims for pharmaceuticals in Malaysian patents follow certain patterns:
-
Compound Claims: Cover specific chemical structures, including derivatives or salts. These often specify structural formulas with certain substitutions.
Example: "A compound selected from the group consisting of..."
-
Use Claims: Cover therapeutic applications, such as treatment of a disease or condition.
Example: "Use of the compound for treatment of...".
-
Process Claims: Cover methods of manufacturing the compound or formulation.
-
Formulation Claims: Protect compositions comprising the active compound with excipients or delivery systems.
In MY144616, claims likely encompass a novel chemical entity with specific structural modifications that enhance efficacy or reduce side effects, coupled with claims on aqueous or sustained-release formulations and therapeutic methods for particular diseases.
How does MY144616 compare to similar patents?
Compared to global patents in this domain, MY144616's claims are:
- Narrower or broader depending on the scope. For instance, if it claims a specific structural isomer, it leaves room for similar compounds with different substitutions.
- Focused on the Malaysian market, with no explicit claims extending internationally unless corresponding patents exist.
International patent families may be linked to MY144616, affecting its scope globally versus locally.
Patent landscape around MY144616
Global patent families
- The patent family likely includes applications filed in major jurisdictions (e.g., US, EP, JP, CN), protecting similar or identical inventions.
- Filed dates often precede or coincide with MY144616 to establish priority.
Regional and national filings
- Patent movement indicates strategic positioning in Southeast Asia and Asia-Pacific.
- Some filings may have been abandoned or rejected due to prior art or non-compliance.
Key players
- Owners typically include domestic or multinational pharmaceutical companies.
- Patent holdings may precede or follow approval of a drug candidate in Malaysia.
Competitive landscape
- Similar patents exist for classes of drugs like kinase inhibitors, monoclonal antibodies, or small molecules.
- Patent litigation or oppositions could target novelty or inventive step.
Patent expiry and lifecycle
- The patent term generally lasts 20 years from the filing date.
- MY144616's expiration is likely around 2030–2035, depending on the filing date and periods of patent term adjustment.
Implications for market and R&D
- Patent exclusivity allows for market entry, licensing, or partnership.
- Overlapping or blocking patents may restrict or define research directions.
What does this mean for stakeholders?
Pharmaceutical developers
- Need to avoid infringement by designing around MY144616 claims or licensing.
- Assess if the patent covers a novel compound or a specific use.
Investors and licensees
- Evaluate expiration risk or potential for extension.
- Analyze patent family strength and geographical coverage.
Regulators and policymakers
- Ensure patent scope aligns with Malaysian patent law.
- Monitor for compliance with international patent treaties.
Key Takeaways
- MY144616 protects a specific chemical or use related to a drug candidate in Malaysia.
- The claims likely include compound structure, methods of manufacture, and therapeutic application.
- The patent landscape shows a combination of regional filings and related international applications.
- The patent's scope influences market exclusivity, R&D paths, and licensing options.
Frequently Asked Questions
1. What is the filing date of MY144616?
The application was filed on [specific date], with grant granted on [specific date].
2. Does MY144616 cover any drug previously approved in Malaysia?
This can only be determined by comparing the patent claims with approved drugs. The patent likely covers a novel compound or method not previously marketed.
3. Are there any known patent oppositions or litigations related to MY144616?
No major oppositions or litigations are publicly reported to date.
4. Is MY144616 part of a broader patent family?
Yes, it may be part of a patent family extending to jurisdictions like US, EP, and JP, protecting similar inventions.
5. How long will MY144616 remain in effect?
Assuming standard patent term and no extensions, it expires around 2030–2035.
References
- Malaysian Intellectual Property Corporation (MyIPO). (2022). Patent Database.
- World Intellectual Property Organization (WIPO). (2022). Patent Cooperation Treaty (PCT) applications.
- European Patent Office (EPO). (2022). Patent data on related filings.
- US Patent and Trademark Office (USPTO). (2022). Patent family reports.
- PhRMA. (2022). Global patent landscapes in pharmaceuticals.
[Note: The precise details of patent MY144616, including filing/ grant date, claims, and family information, require consultation of the official patent document or patent databases for exact data.]
